Grant✓ Small businesses may apply
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health
Award ceiling
$1,500,000
- Opportunity #
- PAR-25-297
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.866
- Status
- posted
- Posted
- Dec 4, 2024
- Closes
- Nov 5, 2027
- Funding instrument
- Cooperative Agreement
- Category
- Health
- Cost sharing required
- No
Who can apply
- •Independent school districts
- •City or township governments
- •For profit organizations other than small businesses
- •Public and State controlled institutions of higher education
- •Native American tribal governments (Federally recognized)
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Public housing authorities/Indian housing authorities
- •Private institutions of higher education
- •State governments
- •County governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Small businesses
- •Special district governments
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Synopsis
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.
Contact
National Institutes of Health · grantsinfo@nih.gov